Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators

Junichi Nakamura, Ichizo Tsuzino, Takahiro Sato, Hiroshi Ohira, Satoshi Itaya, Chisa Takashina-Goto, Taku Watanabe, Masaru Suzuki, Satoshi Konno, Masaharu Nishimura
European Respiratory Journal 2015 46: PA3767; DOI: 10.1183/13993003.congress-2015.PA3767
Junichi Nakamura
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ichizo Tsuzino
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takahiro Sato
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hiroshi Ohira
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Itaya
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Chisa Takashina-Goto
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Taku Watanabe
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaru Suzuki
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Satoshi Konno
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masaharu Nishimura
First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Background: Recent studies have shown that pulmonary arterial hypertension (PAH)-approved vasodilators improve right ventricular (RV) function in PAH. However, it remains unknown whether PAH-approved drugs also improve RV morphology and function in lung disease-associated pulmonary hypertension (group 3 PH).

Aim: To evaluate the RV morphology and systolic function in patients with group 3 PH treated with PAH-approved vasodilators.

Methods: Consecutive patients with severe group 3 PH, defined as mean pulmonary arterial pressure ≥ 35 mmHg or cardiac index < 2 L/min/m2, were studied. Right heart catheterization and cardiac magnetic resonance imaging were performed at baseline and at 3–4 months follow-up, during which the patients received an optimal medical treatment including oxygen plus sildenafil with or without other PAH-approved drug(s).

Results: A total of 10 patients were enrolled in the study (mean age, 66 ±15 years). Their underlying lung diseases were combined pulmonary fibrosis and emphysema (n = 5), interstitial pneumonia (n = 2), chronic obstructive pulmonary disease (n = 2), and cystic lung disease (n = 1). One patient died during the follow-up period. Compared with the baseline data, the follow-up data (n = 9) indicated significant decrease in RV end-diastolic volume index (125 ± 13 to 96 ± 7 mL/m2, p = 0.013) and pulmonary vascular resistance (11.8 ± 1.5 to 7.5 ±1.0 W.U., p = 0.014), and an increase in RV ejection fraction (24% ± 3% to 35% ± 4%, p = 0.015).

Conclusion: PAH-approved drug treatment improves RV dilatation and systolic function in patients with severe group 3 PH.

  • Pulmonary hypertension
  • Treatments
  • Copyright ©ERS 2015
Previous
Back to top
Vol 46 Issue suppl 59 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
Junichi Nakamura, Ichizo Tsuzino, Takahiro Sato, Hiroshi Ohira, Satoshi Itaya, Chisa Takashina-Goto, Taku Watanabe, Masaru Suzuki, Satoshi Konno, Masaharu Nishimura
European Respiratory Journal Sep 2015, 46 (suppl 59) PA3767; DOI: 10.1183/13993003.congress-2015.PA3767

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Amelioration of right ventricular morphology and systolic function in patients with severe group 3 pulmonary hypertension treated with pulmonary vasodilators
Junichi Nakamura, Ichizo Tsuzino, Takahiro Sato, Hiroshi Ohira, Satoshi Itaya, Chisa Takashina-Goto, Taku Watanabe, Masaru Suzuki, Satoshi Konno, Masaharu Nishimura
European Respiratory Journal Sep 2015, 46 (suppl 59) PA3767; DOI: 10.1183/13993003.congress-2015.PA3767
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Temporal hemodynamic and histological changes in a rat model of SUGEN-induced PAH
  • Caspase inhibition stabilizes progressive vascular remodeling in established pulmonary hypertension
  • Cystic fibrosis transmembrane conductance regulator and sphingolipids regulate hypoxic pulmonary vasoconstriction
Show more 4.3 Pulmonary Circulation and Pulmonary Vascular Disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society